tyb
FORTE10 Q-4A Global Hawk drone over southern Bulgaria
Avantor, Inc sold by Goldman Sachs & Co.: $300.34m-August 21
Secondary offering-Form 8K
On August 19, 2020, Avantor, Inc. (the "Company") entered into an Underwriting Agreement (the "Underwriting Agreement"), by and among the Company, the selling stockholders named therein (collectively, the "Selling Stockholders"), and Goldman Sachs & Co. LLC and J.P. Morgan Securities LLC, as underwriters named therein (the "Underwriters"), relating to an underwritten offering of 55,555,555 shares (the "Offered Shares") of the Company's common stock, par value $0.01 per share ("Common Stock"), pursuant to the Company's Registration Statement on Form S-3 (File No. 333-248127), filed on August 19, 2020. The Selling Stockholders also granted the Underwriters a 30-day option to purchase up to 8,333,333 additional shares of Common Stock (the "Option Shares" and, together with the Offered Shares, the "Shares"), which was exercised in full. Pursuant to the Underwriting Agreement, the Selling Stockholders sold the shares for gross proceeds of approximately $1,246 million. The Company did not receive any proceeds from the offering. The offering of the Shares was completed on August 21, 2020.
https://www.marketscreener.com/quote/stock/AVANTOR-INC-58388950/news/AVANTOR-INC-Entry-into-a-Material-Definitive-Agreement-Financial-Statements-and-Exhibits-form-31157647/
Avantor, Inc. is a global provider of mission critical products and services. Its products include materials and consumables, equipment and instrumentation, and services and specialty procurement. Materials and consumables includes chemicals and reagents, lab products and supplies, specialized formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits and education and microbiology and clinical trial kits. Equipment and instrumentation includes filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets and critical environment supplies. Services and specialty procurement include onsite lab and production, clinical, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services. Number of employees : 12 000 people.
https://www.marketscreener.com/quote/stock/AVANTOR-INC-58388950/company/
The Goldman Sachs Group, Inc. specializes in investment services. Revenues break down by activity as follows:
-
investment services (40.5%): involved in the stock, interest, exchange, raw material, and other;
-
asset management (24.5%).
-
investment banking (20.8%): consulting for merger-acquisitions, stock operations, etc.;
-
lending to retail and corporate clients (14.2%). The group is also makes investments in fast growing technology companies.
Revenues are distributed geographically as follows: Americas (60.6%), Europe/Middle East/Africa (26.7%) and Asia (12.7%). Number of employees : 38 300 people.
Also Filed under Avantor BoD memeber
Jo Natauri has served on our Board since November 2018. Ms. Natauri is a Managing Director and the global head of Healthcare Investing within the Merchant Banking Division (MBD) of Goldman Sachs, a position she has held since May 2018. In her current role, Ms. Natauri oversees a portfolio of investments and serves on the boards, or as an observer on the boards, of several MBD portfolio companies. Prior to assuming her current role in MBD, Ms. Natauri was an investment banker with Goldman Sachs for 12 years, where she led coverage of large cap companies in healthcare and other industries. She was named managing director in 2008 and partner in 2012. Ms. Natauri serves on the board of Safe Horizon, the nation’s leading victim assistance organization. Ms. Natauri earned a B.A. in economics and biology from the University of Virginia. Ms. Natauri’s senior management experience as a Managing Director of Goldman Sachs, board and advisory experience with other companies in the life sciences industry and her experience in the areas of finance, strategy and international business transactions, along with her independence, make her a valuable member of our Board.
https://ir.avantorsciences.com/investors/governance/board-of-directors/default.aspx
https://www.finviz.com/insidertrading.ashx?oc=1776123&tc=7&b=2